EN | FR | ES | CN | RU

Mars 2012, Respire, Inspire, Focus ! Lallemand Pharma est heureux de vous annoncer le lancement d’une lettre d’information thématique destinée aux clients de ses lysats bactériens (Ismigen..). L’objectif de ce nouvel outil marketing est d’informer et … d’inspirer les forces de vente de nos distributeurs en rassemblant les informations les plus récentes à propos d’une condition médicale ou d’une maladie pour laquelle les lysats bactériens peuvent être appliqués. Chaque édition de cette lettre intitulée ‘Respire Inspire Focus on…’ fournit des informations médicales élémentaires sur la maladie en question: définition, diagnostic, prévalences, thérapies existantes, et se concentre ensuite sur les lysats bactériens mécaniques et leur rôle potentiel dans la gestion et la prévention de cette maladie en se basant sur l’ensemble des résultats cliniques impliquant nos lysats. Enfin, dans chaque édition nous inviterons un leader d’opinion à partager son point de vue et ses recommandations sur l’application des lysats bactériens en clinique. Une nouvelle édition de cette lettre sera disponible tous les 2 mois, en fonction de la saisonnalité des conditions traitées. Le premier numéro a pour sujet la bronchopneumopathie chronique obstructive (BPCO), une condition qui touche plus de 210 millions de personnes à travers le monde et ne cesse de progresser. Nous sommes fiers pour ce premier numéro d’avoir pu interviewer Pr. Mario Cazzola, Professeur Associé de Médecine Respiratoire et Directeur de l’école postdoctorale de Médecine Respiratoire à l’université de Tor Vergata, Rome, Italie. | 14 Novembre 2011, Lancement d'Ismigen en Géorgie Nouveau lancement des lysats bactériens de Lallemand Pharma (Ismigen®) en Géorgie, où les maladies respiratoires chroniques seraient largement sous-estimées Nous sommes heureux d’annoncer que nos lysats bactériens (Polyvalent Mechanical Bacterial Lysates) viennent d’être lancés en Géorgie par notre partenaire GM Pharmaceuticals, la seule société accréditée BPF pharma en Géorgie. Les lysats sont enregistrés en tant que médicaments et seront vendus sous le nom ISMIGEN®. Pour marquer le lancement officiel, le Professeur Clive Page du King’s College de Londres, un expert en pneumologie réputé, a donné à Tbilisi le 18 Octobre, une conférence sur les bénéfices des lysats bactériens dans la prévention des infections respiratoires, telles la maladie pulmonaire obstructive chronique (MPOC) ou la bronchite, devant 70 pneumologues. Une étude récente (Chkhaidze, 2009) indique que la prévalence des maladies respiratoires chroniques serait très largement sous-estimée en Géorgie et estime que 365 personnes/100.000 seraient affectées, soit 5 fois plus que les statistiques officielles. D’après l’Organisation Mondiale de la Santé, 210 millions de personnes dans le monde souffriraient de MPOC, qui serait en passe de devenir la 3ème cause de mortalité dans le monde d’ici 2030 (source: OMS, 2007). | 1er. Juin 2011 Une étude sur les lysats bactériens de Lallemand (Ismigen) présentée devant 300 médecins au dernier Congrès Sud Américain sur l’asthme et les allergies Les lysats mécaniques bactériens de Lallemand, ou vaccins oraux (PMBL, distribués sous différentes marques selon le pays: Ismigen®, Immubron®, Respibron®, PIR-05®, Provax) se sont invités au dernier Congrès Sud Américain sur l’Asthme et les Allergies qui se déroulait fin avril à Cordoba, en Argentine. Le Professeur Melioli, de l’université de Gènes (Italie) y présenta les résultats préliminaires d’un étude clinique randomisée en double aveugle chez des patients atteints de maladie pulmonaire obstructive chronique (MPOC). Cette étude apporte de nouvelles preuves du fort potentiel immunogène de nos lysats bactériens in vivo et notamment leur capacité à stimuler les deux types de réponse immunitaire, acquise et innée. La présentation du Prof. Melioli avait lieu dans le cadre d’un symposium dédié aux lysats bactériens mécaniques, organisé par Lallemand Pharma en partenariat avec notre distributeur, Merck/Merck Serono Amérique Latine, et qui attira plus de 300 médecins. | May 2nd 2011 : New COPD clinical study presented at the IV World Asthma & COPD Forum in Paris by Pr. Braido Results of the new PMBL clinical study in COPD patients will be presented on Monday 2nd May during the IV World Asthma & COPD Forum in Paris, as part of a symposium dedicated to Bacterial Lysates and Chaired by Pr. Braido from University of Genoa (Italy). Content of the Satellite Symposium sponsored by Lallemand Pharma (Monday, May 2, 17.00 – 18.00, Paris Marriott Rive Gauche Hotel & Conference Centre, LA SEINE Meeting Room B) Guido Ferlazzo, University of Messina, Italy: Immune system cellular cross-talk in the presence of bacterial components Fulvio Braido, University of Genoa: Polyvalent mechanical bacterial lysate treatment in COPD: New immunological evidence The IV World Asthma & COPD Forum is organized by the World Immunopathology Organization and takes place in Paris April 30-May 3. This Congress is mainly dedicated to allergologists, pulmonologists, immunologists, paediatricians, dermatologists, and critical care physicians. The lectures and discussions will cover every aspect of basic research in the field of asthma, COPD and respiratory allergy, and will also bring forth the latest innovations in treatment. More info on http://wipocis.org | May 2nd, 2011 The World Immunopathology Organization (WIPO) organizes the World Asthma & COPD Day. The prevalence of asthma and COPD around the world, their severity and mortality rates allow us to consider them as the most socially significant diseases of today and the nearest future. | April 29th, 2011 : COPD clinical study unveiled at the South American Congress of Allergy and Asthma by Pr. Melioli. A new double blind placebo controlled study has been conducted with PMBL (Ismigen/Immubron®), in order to analyse their immunological effects in vivo, in COPD patients. Results of this study corroborate previous clinical studies in COPD (Cazzola, 2006 & 2009) and bring new evidence of PMBL immunogenic potential in vivo, stimulating both the innate and specific immune response. This new study will be presented for the first time by Pr. Melioli, from University of Genoa, on April 29th in Cordoba (Argentina) during the South American Congress of Allergy and Asthma 2011. This presentation will be part of a symposium jointly organised with Merck, our distributor in Latin american countries , and titled: Respiratory infections, immunity and polyvalent mechanical bacterial lysates (PMBL). The clinical study will be introduced by Pr Anahi Yanez, Director of the Institute of Allergy and Respiratory diseases in Buenos Aires and co-president of the Congress. Pr Sanchez Borges, Chief of the department of Allergy and Immunology at the Medical center Trinidad de Ensenanza in Caracas, will then present a review of PMBL clinical results. Professor Melioli is Director of the Department of Experimental and Laboratory Medicine at the Institute Giannina Gaslini in Genoa in Italy. He is also Professor of Biotech Application in Diagnosis, Clinical Pathology (School of Pediatrics) and Laboratory Management (School of Clinical Pathology) at the University of Genoa. He supervised the clinical study. The South American Congress of Allergy and Asthma 2011 takes place in Cordoba, Argentina, from April 28th to 30th. It is a multidisciplinary forum for allergists, pulmonologists, ENTs, dermatologists, clinicians, pediatricians and primary care physicians to discuss the present and latest advances in allergy and immunology diseases with high impact in South America. More information on http://www.alergiayasma2011.org/en/ | 17 janvier 2011 Lancement d’Ismigen au Sri Lanka par Lifeline Pharmaceuticals Nous sommes heureux d’annoncer que notre Lysat Bactérien mécanique polyvalent, ou vaccin oral Ismigen vient d’être lancé sur le marché Sri lankais par notre partenaire Lifeline Pharmaceuticals. A l’occasion du lancement d’Ismigen, Lallemand Pharma et Lifeline Pharmaceuticals avaient organisé un séminaire à Colombo destiné aux spécialistes des voies respiratoires : pneumologues, ORL etc. Le Professeur Mario Cazzola, Chef de l’Unité de Pharmacologie Clinique respiratoire à Rome (Université Tor Vergata) et un expert reconnu des maladies respiratoires, a donné une présentation sur le bien-fondé des lysats bactériens mécaniques polyvalents dans la prophylaxie des infections respiratoires. D’après le dernier rapport de la World Lung Foundation, les infections respiratoires aigües, décrites comme une pandémie oubliée, sont responsables de plus de 4 millions de décès par an dans le monde et représentent la troisième cause de mortalité et la principale source de maladies et de décès chez les enfants (source: World Lung Foundation, novembre 2010). | 7 janvier 2011 Lancement d’Ismigen en Pologne par notre partenaire GSK Lallemand Pharma Europe et son partenaire GlaxoSmithKline (GSK) lancent le lysat bactérien mécanique polyvalent ISMIGEN® en Pologne. A cette occasion, GSK avait organisé le 7 janvier 2011 un symposium destiné aux pneumologues et allergologues. ISMIGEN® est produit par Lallemand. Ismigen est recommandé pour la prévention des infections subaigües, aigües, et chroniques des voies respiratoires hautes et basses et de l’arbre bronchopulmonaire. D’après l’Organisation Mondiale de la Santé(OMS), les maladies respiratoires sont en pleine expansion et représentent un problème de santé publique majeur à travers le monde. Le symposium de Varsovie fut l’opportunité de faire le point sur les données scientifiques et les applications cliniques d’ISMIGEN. Le Professeur Mario Cazzola, Chef de l’Unité de Pharmacologie Clinique respiratoire à Rome (Université Tor Vergata), a donné une présentation intitulée: ‘Rôle des extraits bactériens dans la prévention des exacerbations aigües de la bronchopneumopathie chronique obstructive (BPCO).’ D’après les plus récentes estimations de l’OMS, 210 millions de personnes à travers le monde seraient atteintes de BPCO, et le nombre de décès liés à cette condition atteignait 3 millions en 2005. L’OMS estime que la BPCO pourrait représenter la troisième cause de mortalité dans le monde d’ici 2030 (source : OMS, 2007). | November,19, 2010 The Journal of the World Allergy Organization recently published a review of literature about the immunomodulatory effects and clinical efficacy of bacterial lysates, concluding to a “ positive trend in terms of overall reduction of infection rates and duration, beneficial effect on symptoms, reduction in antibiotics use and possibility to improve the patient’s quality of life in several diseases.” More specifically, the authors acknowledged the superior immunomodulatory power of Polyvalent Mechanical Bacterial Lysates (Ismigen®; Immubron®, Respibron®; PIR-05®; Provax® - Lallemand Pharma), as compared to Chemical Lysates, both in vitro and in vivo. This is linked to the fact that the mechanical lysis involved in their production process preserves the structure of the bacterial antigen, while chemical lysis leads to ‘lower immunogenicity of the antigens’. The scientific review, written by Prof Canonica and col. from the Allergy Respiratory Disease Department, at University of Genoa in Italy, and Prof. Melioli from Giannina Gaslini Institute in Genoa is available on-line through the Journal of the World Allergy Organization website | October 1st, 2010 Lallemand Pharma International will be present at CpHI Worldwide, the world's leading event for the global pharmaceuticals ingredients industry, which takes place in Paris Villepinte, October 5-7, 2010. Meet us in Hall 6, Booth 6M74. | December 21, 2009 Lallemand Pharma International and Laboratorios Dispert S.A. have signed a distribution agreement for Ismigen in Uruguay. Based in Montevideo, Uruguay, Laboratorios Dispert is the pharmaceutical company that already distributes Lallemand Pharma’s Immubron in Uruguay. | November 19, 2009 Lallemand Pharma International has signed a distribution agreement with Hygis S.A. for the distribution of its immunostimulant PMBL in Switzerland. The Company VP, Mr AMMANN has an extensive experience and in-depth understanding of bacterial lysates applications, making Hygis a partner of choice for the distribution of Ismigen in Switzerland. Hygis SA distributes and markets pharmaceutical and healthcare products in Switzerland. The company is based in Bussy-Chardonney | August 20, 2009 Lallemand Pharma International has signed an agreement with Innofarma for the distribution of Ismigen in Turkey. Based in Istanbul, Innofarma is committed to bringing the highest quality prevention products and services to the healthcare community across Turkey and the region. The company innovative products for preventive medicine include personalized micronutrient modules. More info on: www.innofarma.com | June 5, 2009 Read the news about Ismigen launch in Argentina in Scrip World Pharmaceutical News (by Asher Mullard) http://www.scripnews.com | June 15, 2009 Professor Cazzola to present Ismigen’s latest clinical study at the Annual ERS Congress in Vienna, 15th September 2009 The results of Ismigen latest clinical trial in COPD patients (Cazzola, 2009), will be presented at the 18th Annual European Respiratory Society Congress (ERS), to take place in Vienna, Austria, September 12-16, 2009. The ERS Congress is the world’s largest congress of pulmonary medicine, gathering each year around 17 000 participants from around the world. Ismigen clinical study will be presented by Professor Mario Cazzola, from University of Rome, co-Chairman of the European Respiratory Society/American Thoracic Society Task Force, on Tuesday, 15th September, at 14.45, Room A3. For more information about the ERS Congress, visit www.ersnet.org | May 14, 2009 Results of a pilot clinical study published ahead of time in Therapeutic Advances in Respiratory Disease Online, confirm the potential of Ismigen® in the management of chronic obstructive pulmonary disease (COPD) . The new study, directed by Professor Mario Cazzola (University of Rome, Italy) over a nine month period on 63 patients in total, confirms previous trials. In this study, the administration of Ismigen in addition to regular treatment (salmeterol/fluticasone) reduced the rate of exacerbations per patient per year by 20% (0,54 vs. 0,67 in control group). The immunostimulant drug also reduced the number of exacerbations that needed treatment with oral corticosteroids, as well as the total number of hospitalizations. (Mario Cazzola, Paolo Noschese and Felice Di Perna : “Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone.” Ther Adv Respir Dis.2009; Pubished online May, 14, 2009, DOI: 10.1177/1753465808104677) | May 7, 2009 Lallemand Pharma has signed a distribution agreement for Polyvalent Mechanical Bacterial Lysate in Russia with Makiz Pharma, a branch of German Healthcare company Stada Arzneimittel AG. The product has now entered drug registration process under trade name Respibron. More about Stada: http://www.stada.de/english/home.asp | May 6, 2009 Lallemand Pharma International will be present at Vitafoods in Geneva, Switzerland. This international trade show will be the occasion to meet up with some of our partners and customers. More information about Vitafoods International on: http://www.vitafoods.eu.com/ | April 30, 2009 Lallemand Pharma International has concluded an agreement with Kalbe Farma for the distribution of Ismigen in Indonesia. Kalbe Farma is one of the leading pharmaceuticals and health products companies in Indonesia and is recognized as the largest regional pharmaceutical company in Southeast Asia. More information on http://www.kalbe.co.id/ | April 20, 2009 Following the registration of Polyvalent Bacterial Mechanical Lysates last December, our partner Merck Serono has successfully launched Ismigen in Argentina. The launch was accompanied by a series of medical conferences chaired by Professor Giorgio Walter Canonica (Italy) and Professor Carlos E. Baena-Cagnani (Argentina), in Cordoba, Buenos Aires and Rosario, gathering over 500 physicians. Merck Serono is the division for innovative small molecules and biopharmaceuticals of Merck KGaA . The company has a strong and growing presence on the Argentinean pharmaceutical market with a range of prescription drugs through Merck Química Argentina. More information on: http://www.merck.com.ar/en/index.html | April 2, 2009 Ismigen is now registered in Peru and will be launched by our partner Merck Serono within the coming months. Merck Serono is the division for innovative small molecules and biopharmaceuticals of Pharmaceutical and Chemical company Merck KGaA .The company is present in Peru since 1962 through Merck Peruana S.A. More information on http://www.merck.com.pe/en/index.html | March 26-29, 2009 Lallemand Pharma International takes part in the First Middle East-Asia Allergy Asthma Immunology Congress in Dubai, UAE (MEAAAIC 2009). On Wednesday, 27th March, Professor G. Walter Canonica, President of the World Allergy Organization gives a lecture about the effects and potential of Polyvalent Bacterial Mechanical Lysates, titled: "May we strengthen the human natural defenses with Bacterial Lysate?" A video of his presentation will be posted shortly on this website. For more information about the Congress: http://www.meaaaic.com/index.html | October 10, 2008 Lallemand Pharma International has signed an agreement with Healol Pharmaceuticals for the distribution of Ismigen in Malaysia, Cambodia, Thailand and Vietnam. Healol Pharmaceuticals distributes and markets pharmaceutical products in Malaysia, Cambodia, Lao PDR, Myanmar, Thailand and Vietnam. More information on http://www.healol.com/ | December 4, 2008 Lallemand Pharma International has signed a distribution agreement with APC Pharmaceuticals & Chemical for Respibron in Vietnam. The drug has now entered registration process. Headquartered in Hong Kong, with key offices in China, India, Vietnam, the United Kingdom, Hungary and America, the APC Group is specialised in pharmaceuticals and chemicals, food and beverages, nutritional supplements and technology services. More information on http://www.apcgroup.com | November 5-8, 2008 Lallemand Pharma International sponsors the XIX World Congress of Asthma in Monte Carlo, Monaco, organised by the International Association of Asthmalogy and chaired by Prof. Carlos E. Baena-Cagnani (Argentina), and Prof. G. Walter Canonica (Italy). Program and registration: http://www.aim-internationalgroup.com/2008/wca/index.html | October 4-8, 2008 Lallemand Pharma International is present at the 17th Annual Congress of the European Respiratory Society in Berlin, Germany. Program and registration: http://dev.ersnet.org/412-welcome-address.htm | September 30-October 2, 2008 Lallemand Pharma International exhibits at CPhI Worldwide, the International Congress of Pharmaceutical Ingredients, in Frankfurt (Germany). Meet us on booth 42J40. Registration: www.cphi.com | September 15, 2008 Greek pharmaceutical company Rafarm has completed the registration of Polyvalent Mechanical Bacterial Lysate and will launch the drug on the Greek market under trade name Pir05 by mid-2009. Established in Athens in 1974, Rafarm is today among Greece top ten pharma companies . More information on http://www.rafarm.gr | September 15, 2008 Ismigen is launched in India by Lupin Limited, one of India’s top ten pharmaceutical companies. Headquartered in Mumbai, Lupin Ltd positioned itself as an innovation led transnational pharmaceutical company. Lupin develops and markets a wide range of quality, affordable generic and branded formulations and APIs in multiple markets across the world, with a strong presence in the US. Today, it has a significant presence in Cephalosporins, Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs therapy segments. To support the launch of Ismigen®, Pr. Mario Cazzola, Associate Professor of Respiratory Medicine at the University of Rome, and Dr Frédéric Durmont, General Manager for Lallemand Pharma International will give lectures about Polyvalent Mechanical Bacterial Lysates and their applications during a promotional tour in India aimed at the pharmaceutical/medical community, early December. | September 5, 2008 Lallemand Pharma has signed a distribution agreement with Zuoz Pharma S.A., a leading Venezuelan pharmaceutical company based in Caracas, for the distribution of Ismigen® in Venezuela. More info about our partner: www.zuozpharma.com |

Actualités Expertise Production Clients Nos Partenaires R&D

Accueil > Actualités

Actualités

Prof. G.W.Canonica's lecture

Discover the video of Prof. G.W.Canonica's lecture during The First Middle East Asia Allergy Asthma Congress at Dubai here.
The full quality video will come soon.

Mars 2012, Respire, Inspire, Focus !

Lallemand Pharma est heureux de vous annoncer le lancement d’une lettre d’information thématique destinée aux clients de ses lysats bactériens (Ismigen..).

L’objectif de ce nouvel outil marketing est d’informer et … d’inspirer les forces de vente de nos distributeurs en rassemblant les informations les plus récentes à propos d’une condition médicale ou d’une maladie pour laquelle les lysats bactériens peuvent être appliqués. Chaque édition de cette lettre intitulée ‘Respire Inspire Focus on…’ fournit des informations médicales élémentaires sur la maladie en question: définition, diagnostic, prévalences, thérapies existantes, et se concentre ensuite sur les lysats bactériens mécaniques et leur rôle potentiel dans la gestion et la prévention de cette maladie en se basant sur l’ensemble des résultats cliniques impliquant nos lysats. Enfin, dans chaque édition nous inviterons un leader d’opinion à partager son point de vue et ses recommandations sur l’application des lysats bactériens en clinique. Une nouvelle édition de cette lettre sera disponible tous les 2 mois, en fonction de la saisonnalité des conditions traitées.

Le premier numéro a pour sujet la bronchopneumopathie chronique obstructive (BPCO), une condition qui touche plus de 210 millions de personnes à travers le monde et ne cesse de progresser. Nous sommes fiers pour ce premier numéro d’avoir pu interviewer Pr. Mario Cazzola, Professeur Associé de Médecine Respiratoire et Directeur de l’école postdoctorale de Médecine Respiratoire à l’université de Tor Vergata, Rome, Italie.

14 Novembre 2011, Lancement d'Ismigen en Géorgie

Nouveau lancement des lysats bactériens de Lallemand Pharma (Ismigen®) en Géorgie, où les maladies respiratoires chroniques seraient largement sous-estimées

Nous sommes heureux d’annoncer que nos lysats bactériens (Polyvalent Mechanical Bacterial Lysates) viennent d’être lancés en Géorgie par notre partenaire GM Pharmaceuticals, la seule société accréditée BPF pharma en Géorgie. Les lysats sont enregistrés en tant que médicaments et seront vendus sous le nom ISMIGEN®.

Pour marquer le lancement officiel, le Professeur Clive Page du King’s College de Londres, un expert en pneumologie réputé, a donné à Tbilisi le 18 Octobre, une conférence sur les bénéfices des lysats bactériens dans la prévention des infections respiratoires, telles la maladie pulmonaire obstructive chronique (MPOC) ou la bronchite, devant 70 pneumologues.

Une étude récente (Chkhaidze, 2009) indique que la prévalence des maladies respiratoires chroniques serait très largement sous-estimée en Géorgie et estime que 365 personnes/100.000 seraient affectées, soit 5 fois plus que les statistiques officielles. D’après l’Organisation Mondiale de la Santé, 210 millions de personnes dans le monde souffriraient de MPOC, qui serait en passe de devenir la 3ème cause de mortalité dans le monde d’ici 2030 (source: OMS, 2007).

1er. Juin 2011 Une étude sur les lysats bactériens de Lallemand (Ismigen) présentée devant 300 médecins au dernier Congrès Sud Américain sur l’asthme et les allergies

Les lysats mécaniques bactériens de Lallemand, ou vaccins oraux (PMBL, distribués sous différentes marques selon le pays: Ismigen®, Immubron®, Respibron®, PIR-05®, Provax) se sont invités au dernier Congrès Sud Américain sur l’Asthme et les Allergies qui se déroulait fin avril à Cordoba, en Argentine. Le Professeur Melioli, de l’université de Gènes (Italie) y présenta les résultats préliminaires d’un étude clinique randomisée en double aveugle chez des patients atteints de maladie pulmonaire obstructive chronique (MPOC). Cette étude apporte de nouvelles preuves du fort potentiel immunogène de nos lysats bactériens in vivo et notamment leur capacité à stimuler les deux types de réponse immunitaire, acquise et innée. La présentation du Prof. Melioli avait lieu dans le cadre d’un symposium dédié aux lysats bactériens mécaniques, organisé par Lallemand Pharma en partenariat avec notre distributeur, Merck/Merck Serono Amérique Latine, et qui attira plus de 300 médecins.

May 2nd 2011 : New COPD clinical study presented at the IV World Asthma & COPD Forum in Paris by Pr. Braido

Results of the new PMBL clinical study in COPD patients will be presented on Monday 2^nd May during the IV World Asthma & COPD Forum in Paris, as part of a symposium dedicated to Bacterial Lysates and Chaired by Pr. Braido from University of Genoa (Italy).

Content of the Satellite Symposium sponsored by Lallemand Pharma

(Monday, May 2, 17.00 – 18.00, Paris Marriott Rive Gauche Hotel & Conference Centre, LA SEINE Meeting Room B)

Guido Ferlazzo, University of Messina, Italy:

Immune system cellular cross-talk in the presence of bacterial components

Fulvio Braido, University of Genoa:

Polyvalent mechanical bacterial lysate treatment in COPD: New immunological evidence

The IV World Asthma & COPD Forum is organized by the World Immunopathology Organization and takes place in Paris April 30-May 3. This Congress is mainly dedicated to allergologists, pulmonologists, immunologists, paediatricians, dermatologists, and critical care physicians. The lectures and discussions will cover every aspect of basic research in the field of asthma, COPD and respiratory allergy, and will also bring forth the latest innovations in treatment. More info on http://wipocis.org

May 2nd, 2011

The World Immunopathology Organization (WIPO) organizes the World Asthma & COPD Day.

The prevalence of asthma and COPD around the world, their severity and mortality rates allow us to consider them as the most socially significant diseases of today and the nearest future.

April 29th, 2011 : COPD clinical study unveiled at the South American Congress of Allergy and Asthma by Pr. Melioli.

A new double blind placebo controlled study has been conducted with PMBL (Ismigen/Immubron^®), in order to analyse their immunological effects in vivo, in COPD patients. Results of this study corroborate previous clinical studies in COPD (Cazzola, 2006 & 2009) and bring new evidence of PMBL immunogenic potential in vivo, stimulating both the innate and specific immune response.

This new study will be presented for the first time by Pr. Melioli, from University of Genoa, on April 29^th in Cordoba (Argentina) during the South American Congress of Allergy and Asthma 2011. This presentation will be part of a symposium jointly organised with Merck, our distributor in Latin american countries , and titled: Respiratory infections, immunity and polyvalent mechanical bacterial lysates (PMBL).

The clinical study will be introduced by Pr Anahi Yanez, Director of the Institute of Allergy and Respiratory diseases in Buenos Aires and co-president of the Congress. Pr Sanchez Borges, Chief of the department of Allergy and Immunology at the Medical center Trinidad de Ensenanza in Caracas, will then present a review of PMBL clinical results.

Professor Melioli is Director of the Department of Experimental and Laboratory Medicine at the Institute Giannina Gaslini in Genoa in Italy. He is also Professor of Biotech Application in Diagnosis, Clinical Pathology (School of Pediatrics) and Laboratory Management (School of Clinical Pathology) at the University of Genoa. He supervised the clinical study.

The South American Congress of Allergy and Asthma 2011 takes place in Cordoba, Argentina, from April 28th to 30^th. It is a multidisciplinary forum for allergists, pulmonologists, ENTs, dermatologists, clinicians, pediatricians and primary care physicians to discuss the present and latest advances in allergy and immunology diseases with high impact in South America. More information on http://www.alergiayasma2011.org/en/

17 janvier 2011

Lancement d’Ismigen au Sri Lanka par Lifeline Pharmaceuticals

Nous sommes heureux d’annoncer que notre Lysat Bactérien mécanique polyvalent, ou vaccin oral Ismigen vient d’être lancé sur le marché Sri lankais par notre partenaire Lifeline Pharmaceuticals. A l’occasion du lancement d’Ismigen, Lallemand Pharma et Lifeline Pharmaceuticals avaient organisé un séminaire à Colombo destiné aux spécialistes des voies respiratoires : pneumologues, ORL etc. Le Professeur Mario Cazzola, Chef de l’Unité de Pharmacologie Clinique respiratoire à Rome (Université Tor Vergata) et un expert reconnu des maladies respiratoires, a donné une présentation sur le bien-fondé des lysats bactériens mécaniques polyvalents dans la prophylaxie des infections respiratoires.

D’après le dernier rapport de la World Lung Foundation, les infections respiratoires aigües, décrites comme une pandémie oubliée, sont responsables de plus de 4 millions de décès par an dans le monde et représentent la troisième cause de mortalité et la principale source de maladies et de décès chez les enfants (source: World Lung Foundation, novembre 2010).

7 janvier 2011

Lancement d’Ismigen en Pologne par notre partenaire GSK

Lallemand Pharma Europe et son partenaire GlaxoSmithKline (GSK) lancent le lysat bactérien mécanique polyvalent ISMIGEN^® en Pologne. A cette occasion, GSK avait organisé le 7 janvier 2011 un symposium destiné aux pneumologues et allergologues. ISMIGEN^® est produit par Lallemand. Ismigen est recommandé pour la prévention des infections subaigües, aigües, et chroniques des voies respiratoires hautes et basses et de l’arbre bronchopulmonaire. D’après l’Organisation Mondiale de la Santé(OMS), les maladies respiratoires sont en pleine expansion et représentent un problème de santé publique majeur à travers le monde.

Le symposium de Varsovie fut l’opportunité de faire le point sur les données scientifiques et les applications cliniques d’ISMIGEN. Le Professeur Mario Cazzola, Chef de l’Unité de Pharmacologie Clinique respiratoire à Rome (Université Tor Vergata), a donné une présentation intitulée: ‘Rôle des extraits bactériens dans la prévention des exacerbations aigües de la bronchopneumopathie chronique obstructive (BPCO).’

D’après les plus récentes estimations de l’OMS, 210 millions de personnes à travers le monde seraient atteintes de BPCO, et le nombre de décès liés à cette condition atteignait 3 millions en 2005. L’OMS estime que la BPCO pourrait représenter la troisième cause de mortalité dans le monde d’ici 2030 (source : OMS, 2007).

November,19, 2010

The Journal of the World Allergy Organization recently published a review of literature about the immunomodulatory effects and clinical efficacy of bacterial lysates, concluding to a “ positive trend in terms of overall reduction of infection rates and duration, beneficial effect on symptoms, reduction in antibiotics use and possibility to improve the patient’s quality of life in several diseases.”

More specifically, the authors acknowledged the superior immunomodulatory power of Polyvalent Mechanical Bacterial Lysates (Ismigen^®; Immubron^®,Respibron^®; PIR-05^®; Provax^® -Lallemand Pharma), as compared to Chemical Lysates, both in vitro and in vivo. This is linked to the fact that the mechanical lysis involved in their production process preserves the structure of the bacterial antigen, while chemical lysis leads to ‘lower immunogenicity of the antigens’.

The scientific review, written by Prof Canonica and col. from the Allergy Respiratory Disease Department, at University of Genoa in Italy, and Prof. Melioli from Giannina Gaslini Institute in Genoa is available on-line through the Journal of the World Allergy Organization website

October 1st, 2010

Lallemand Pharma International will be present at CpHI Worldwide, the world's leading event for the global pharmaceuticals ingredients industry, which takes place in Paris Villepinte, October 5-7, 2010. Meet us in Hall 6, Booth 6M74.

December 21, 2009

Lallemand Pharma International and Laboratorios Dispert S.A. have signed a distribution agreement for Ismigen in Uruguay.

Based in Montevideo, Uruguay, Laboratorios Dispert is the pharmaceutical company that already distributes Lallemand Pharma’s Immubron in Uruguay.

November 19, 2009

Lallemand Pharma International has signed a distribution agreement with Hygis S.A. for the distribution of its immunostimulant PMBL in Switzerland. The Company VP, Mr AMMANN has an extensive experience and in-depth understanding of bacterial lysates applications, making Hygis a partner of choice for the distribution of Ismigen in Switzerland.

Hygis SA distributes and markets pharmaceutical and healthcare products in Switzerland. The company is based in Bussy-Chardonney

August 20, 2009

Lallemand Pharma International has signed an agreement with Innofarma for the distribution of Ismigen in Turkey.

Based in Istanbul, Innofarma is committed to bringing the highest quality prevention products and services to the healthcare community across Turkey and the region. The company innovative products for preventive medicine include personalized micronutrient modules.

More info on: www.innofarma.com

June 5, 2009

Read the news about Ismigen launch in Argentina in Scrip World Pharmaceutical News (by Asher Mullard)

http://www.scripnews.com

June 15, 2009

Professor Cazzola to present Ismigen’s latest clinical study at the Annual ERS Congress in Vienna, 15^th September 2009

The results of Ismigen latest clinical trial in COPD patients (Cazzola, 2009), will be presented at the 18^th Annual European Respiratory Society Congress (ERS), to take place in Vienna, Austria, September 12-16, 2009. The ERS Congress is the world’s largest congress of pulmonary medicine, gathering each year around 17 000 participants from around the world.

Ismigen clinical study will be presented by Professor Mario Cazzola, from University of Rome, co-Chairman of the European Respiratory Society/American Thoracic Society Task Force, on Tuesday, 15^th September, at 14.45, Room A3. For more information about the ERS Congress, visit www.ersnet.org

May 14, 2009

Results of a pilot clinical study published ahead of time in Therapeutic Advances in Respiratory Disease Online, confirm the potential of Ismigen® in the management of chronic obstructive pulmonary disease (COPD) .

The new study, directed by Professor Mario Cazzola (University of Rome, Italy) over a nine month period on 63 patients in total, confirms previous trials.

In this study, the administration of Ismigen in addition to regular treatment (salmeterol/fluticasone) reduced the rate of exacerbations per patient per year by 20% (0,54 vs. 0,67 in control group). The immunostimulant drug also reduced the number of exacerbations that needed treatment with oral corticosteroids, as well as the total number of hospitalizations.

(Mario Cazzola, Paolo Noschese and Felice Di Perna : “Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone.” Ther Adv Respir Dis.2009; Pubished online May, 14, 2009, DOI: 10.1177/1753465808104677)

May 7, 2009

Lallemand Pharma has signed a distribution agreement for Polyvalent Mechanical Bacterial Lysate in Russia with Makiz Pharma, a branch of German Healthcare company Stada Arzneimittel AG. The product has now entered drug registration process under trade name Respibron.

More about Stada: http://www.stada.de/english/home.asp

May 6, 2009

Lallemand Pharma International will be present at Vitafoods in Geneva, Switzerland. This international trade show will be the occasion to meet up with some of our partners and customers. More information about Vitafoods International on: http://www.vitafoods.eu.com/

April 30, 2009

Lallemand Pharma International has concluded an agreement with Kalbe Farma for the distribution of Ismigen in Indonesia.

Kalbe Farma is one of the leading pharmaceuticals and health products companies in Indonesia and is recognized as the largest regional pharmaceutical company in Southeast Asia. More information on http://www.kalbe.co.id/

April 20, 2009

Following the registration of Polyvalent Bacterial Mechanical Lysates last December, our partner Merck Serono has successfully launched Ismigen in Argentina.

The launch was accompanied by a series of medical conferences chaired by Professor Giorgio Walter Canonica (Italy) and Professor Carlos E. Baena-Cagnani (Argentina), in Cordoba, Buenos Aires and Rosario, gathering over 500 physicians.

Merck Serono is the division for innovative small molecules and biopharmaceuticals of Merck KGaA . The company has a strong and growing presence on the Argentinean pharmaceutical market with a range of prescription drugs through Merck Química Argentina. More information on: http://www.merck.com.ar/en/index.html

April 2, 2009

Ismigen is now registered in Peru and will be launched by our partner Merck Serono within the coming months.

Merck Serono is the division for innovative small molecules and biopharmaceuticals of Pharmaceutical and Chemical company Merck KGaA .The company is present in Peru since 1962 through Merck Peruana S.A. More information on http://www.merck.com.pe/en/index.html

March 26-29, 2009

Lallemand Pharma International takes part in the First Middle East-Asia Allergy Asthma Immunology Congress in Dubai, UAE (MEAAAIC 2009).

On Wednesday, 27th March, Professor G. Walter Canonica, President of the World Allergy Organization gives a lecture about the effects and potential of Polyvalent Bacterial Mechanical Lysates, titled: "May we strengthen the human natural defenses with Bacterial Lysate?"

A video of his presentation will be posted shortly on this website.

For more information about the Congress: http://www.meaaaic.com/index.html

October 10, 2008

Lallemand Pharma International has signed an agreement with Healol Pharmaceuticals for the distribution of Ismigen in Malaysia, Cambodia, Thailand and Vietnam.

Healol Pharmaceuticals distributes and markets pharmaceutical products in Malaysia, Cambodia, Lao PDR, Myanmar, Thailand and Vietnam. More information on http://www.healol.com/

December 4, 2008

Lallemand Pharma International has signed a distribution agreement with APC Pharmaceuticals & Chemical for Respibron in Vietnam. The drug has now entered registration process.

Headquartered in Hong Kong, with key offices in China, India, Vietnam, the United Kingdom, Hungary and America, the APC Group is specialised in pharmaceuticals and chemicals, food and beverages, nutritional supplements and technology services. More information on http://www.apcgroup.com

November 5-8, 2008

Lallemand Pharma International sponsors the XIX World Congress of Asthma in Monte Carlo, Monaco, organised by the International Association of Asthmalogy and chaired by Prof. Carlos E. Baena-Cagnani (Argentina), and Prof. G. Walter Canonica (Italy).

Program and registration: http://www.aim-internationalgroup.com/2008/wca/index.html

October 4-8, 2008

Lallemand Pharma International is present at the 17th Annual Congress of the European Respiratory Society in Berlin, Germany. Program and registration: http://dev.ersnet.org/412-welcome-address.htm

September 30-October 2, 2008

Lallemand Pharma International exhibits at CPhI Worldwide, the International Congress of Pharmaceutical Ingredients, in Frankfurt (Germany). Meet us on booth 42J40. Registration: www.cphi.com

September 15, 2008

Greek pharmaceutical company Rafarm has completed the registration of Polyvalent Mechanical Bacterial Lysate and will launch the drug on the Greek market under trade name Pir05 by mid-2009.

Established in Athens in 1974, Rafarm is today among Greece top ten pharma companies . More information on http://www.rafarm.gr

September 15, 2008

Ismigen is launched in India by Lupin Limited, one of India’s top ten pharmaceutical companies. Headquartered in Mumbai, Lupin Ltd positioned itself as an innovation led transnational pharmaceutical company. Lupin develops and markets a wide range of quality, affordable generic and branded formulations and APIs in multiple markets across the world, with a strong presence in the US. Today, it has a significant presence in Cephalosporins, Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs therapy segments.

To support the launch of Ismigen®, Pr. Mario Cazzola, Associate Professor of Respiratory Medicine at the University of Rome, and Dr Frédéric Durmont, General Manager for Lallemand Pharma International will give lectures about Polyvalent Mechanical Bacterial Lysates and their applications during a promotional tour in India aimed at the pharmaceutical/medical community, early December.

September 5, 2008

Lallemand Pharma has signed a distribution agreement with Zuoz Pharma S.A., a leading Venezuelan pharmaceutical company based in Caracas, for the distribution of Ismigen® in Venezuela.

More info about our partner: www.zuozpharma.com

Accéder aux archives »